amarin corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. vascepa® (icosapent ethyl) is amarin's first fda approved product and is available in the united states by prescription. for more information about vascepa visit www.vascepa.com.
Company profile
Ticker
AMRN
Exchange
Website
CEO
John Thero
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMARIN PHARMACEUTICALS PLC, ETHICAL HOLDINGS PLC
SEC CIK
Corporate docs
Subsidiaries
Amarin Pharmaceuticals Ireland Limited • Amarin Pharma, Inc. • Ester Neurosciences Limited • Amarin Switzerland GmbH • Amarin Germany GmbH • Amarin France SAS • Amarin UK Limited • Amarin Belgium, branch of Amarin Switzerland GmbH • Amarin Denmark, filial af Amarin Switzerland GmbH • Amarin Switzerland GmbH ...
AMRN stock data
Latest filings (excl ownership)
8-K
Amarin Announces Results of Annual General Meeting of Shareholders
22 Apr 24
8-K
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
3 Apr 24
ARS
2023 FY
Annual report to shareholders
4 Mar 24
DEF 14A
Definitive proxy
4 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
29 Feb 24
PRE 14A
Preliminary proxy
12 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
26 Jan 24
8-K
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities for 2024
10 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Nov 23
Transcripts
AMRN
Earnings call transcript
2023 Q4
29 Feb 24
AMRN
Earnings call transcript
2023 Q3
1 Nov 23
AMRN
Earnings call transcript
2023 Q1
3 May 23
AMRN
Earnings call transcript
2022 Q4
1 Mar 23
AMRN
Earnings call transcript
2022 Q3
27 Oct 22
AMRN
Earnings call transcript
2022 Q2
3 Aug 22
AMRN
Earnings call transcript
2022 Q1
4 May 22
AMRN
Earnings call transcript
2021 Q4
1 Mar 22
AMRN
Earnings call transcript
2021 Q3
3 Nov 21
AMRN
Earnings call transcript
2021 Q2
5 Aug 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 270.81 mm | 270.81 mm | 270.81 mm | 270.81 mm | 270.81 mm | 270.81 mm |
Cash burn (monthly) | (no burn) | (no burn) | 7.15 mm | 6.03 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 48.72 mm | 41.08 mm | n/a | n/a |
Cash remaining | n/a | n/a | 222.09 mm | 229.74 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | 31.1 | 38.1 | n/a | n/a |
Institutional ownership, Q4 2023
81.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 140 |
Opened positions | 15 |
Closed positions | 56 |
Increased positions | 27 |
Reduced positions | 33 |
13F shares | Current |
---|---|
Total value | 68.60 bn |
Total shares | 80.56 mm |
Total puts | 14.10 k |
Total calls | 23.00 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Sarissa Capital Management | 24.85 mm | $21.62 bn |
Kynam Capital Management | 12.02 mm | $10.46 bn |
Eversept Partners | 6.10 mm | $5.30 bn |
MS Morgan Stanley | 5.56 mm | $4.84 bn |
DG Capital Management | 5.41 mm | $4.70 bn |
Tang Capital Management | 3.09 mm | $2.69 bn |
SCP Investment | 2.50 mm | $3.14 bn |
Price Jennifer C. | 2.38 mm | $2.07 bn |
Longitude | 2.05 mm | $1.78 bn |
Hayek Kallen Investment Management | 1.02 mm | $885.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | DiPaolo Mark | RSU Ordinary Shares | Grant | Acquire A | No | No | 0 | 50,287 | 0.00 | 50,287 |
18 Apr 24 | DiPaolo Mark | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 0.87 | 179,795 | 156.42 k | 179,795 |
18 Apr 24 | Patrice Eadon Bonfiglio | RSU Ordinary Shares | Grant | Acquire A | No | No | 0 | 50,287 | 0.00 | 50,287 |
18 Apr 24 | Patrice Eadon Bonfiglio | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 0.87 | 179,795 | 156.42 k | 179,795 |
18 Apr 24 | Oliver O'Connor | RSU Ordinary Shares | Grant | Acquire A | No | No | 0 | 50,287 | 0.00 | 50,287 |
18 Apr 24 | Oliver O'Connor | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 0.87 | 179,795 | 156.42 k | 179,795 |
18 Apr 24 | Odysseas Kostas D | RSU Ordinary Shares | Grant | Acquire A | No | No | 0 | 50,287 | 0.00 | 50,287 |
18 Apr 24 | Odysseas Kostas D | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 0.87 | 179,795 | 156.42 k | 179,795 |
18 Apr 24 | Keith Horn | RSU Ordinary Shares | Grant | Acquire A | No | No | 0 | 50,287 | 0.00 | 50,287 |
18 Apr 24 | Keith Horn | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 0.87 | 179,795 | 156.42 k | 179,795 |
News
Amarin Highlights Key Data Providing Mechanistic Insights Into Eicosapentaenoic Acid At ACC.24
8 Apr 24
Amarin Announces Research Evaluating Benefits Of VASCEPA/VAZKEPA To Be Presented At The American College Of Cardiology's Annual Scientific Session & Expo
25 Mar 24
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
29 Feb 24
Why Is Amarin Stock Trading Lower After Q4 Earnings?
29 Feb 24
Amarin Corp Q4 Adj EPS $0.00 Beats $(0.03) Estimate, Sales $74.71M Beat $63.81M Estimate
29 Feb 24
Press releases
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
8 Apr 24
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
6 Apr 24
HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan
6 Feb 24